Comment
Author: Admin | 2025-04-28
Syndrome * CAPITALS indicate life-threatening.Underline indicate most frequent.InteractionsDrug-Drug Carbamazepine, phenobarbital, phenytoin, rifampin and nevirapine ↓ blood levels and effectiveness; concurrent use contraindicated.↑ levels and risk of serious toxicity with alfuzosin, dihydroergotamine, dronedarone, ergotamine, irinotecan, lomitapide, lovastatin, lurasidone, methylergonovine, pimozide, ranolazine, sildenafil (for pulmonary hypertension), simvastatin, and triazolam ; concurrent use contraindicated.↑ levels and risk of serious toxicity with colchicine ; concurrent use contraindicated in patients with renal or hepatic impairment.↑ risk of hepatotoxicity with elbasvir/grazoprevir and glecaprevir/pibrentasvir ; concurrent use contraindicated.Concurrent use with drospirenone/ethinyl estradiol may ↑ drospirenone levels and risk of hyperkalemia; concurrent use contraindicated.↑ risk of renal impairment with tenofovir disoproxil fumarate ; avoid concurrent use with nephrotoxic agents.Concurrent use with other antiretrovirals that require inhibition of CYP3A for adequate exposure especially protease inhibitors (may ↓ antiretroviral effectiveness).↑ levels and risk of toxicity from some antiarrhythmics (including amiodarone, digoxin, disopyramide, flecainide, mexiletine and propafenone, antineoplastics (including dasatinib, nilotinib, vinblastine and vincristine ), anticonvulsants metabolized by CYP3A (including clonazepam ); monitor drug effects carefully, titrate if necessary and consider alternatives.↑ risk of sedation with sedative/hypnotics, including buspirone, diazepam, midazolam, zolpidem and others metabolized by CYP3A (careful monitoring with dose reduction recommended).Absorption of atazanavir may be ↓ by proton-pump inhibitors (administer 12 hr after PPI, dose should not >20 mg omeprazole or equivalent/day, not recommended in treatment-experienced patients), antacids (separate dose by 2 hr), buffered medications, H2 -receptor antagonists (administer famotidine at same time or at least 10 hr after famotidine [dose should not exceed famotidine 40 mg twice daily or equivalent in treatment-naïve patients or 20 mg twice daily or equivalent in treatment-experienced patients]).Concurrent use with efavirenz or etravirine may ↓ levels and effectiveness (concurrent use is not recommended).↑ levels of maraviroc (↓ dose of maraviroc to 150 mg twice daily).↑ levels and risk of adverse reactions from clarithromycin
Add Comment